Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

VistaGen Therapeutics Inc (VTGN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow VistaGen Therapeutics's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.620 +0.120    +2.66%
13:26:57 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 74,413
  • Bid/Ask: 0.000 / 0.000
  • Day's Range: 4.530 - 4.670
Type:  Equity
Market:  United States
VistaGen Therapeutics 4.620 +0.120 +2.66%

VistaGen Therapeutics Inc Company Profile

 
Get an in-depth profile of VistaGen Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

32

Equity Type

ORD

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company’s pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Contact Information

Address 343 Allerton Avenue
South San Francisco, 94080
United States
Phone 650 577 3600
Fax 888 482 2602

Top Executives

Name Age Since Title
Shawn K. Singh 58 2000 CEO & Director
Gordon Keller - 2022 Chairman of Scientific Advisory Board
Sanjay Johan Mathew - 2016 Member of Clinical & Regulatory Advisory Board
Jerry B. Gin 80 2016 Independent Director
Thomas P. Laughren - 2016 Member of Clinical & Regulatory Advisory Board
Mark A. Smith 68 2016 Member of the Advisory Board
Michael B. Liebowitz - 2018 Member of CNS Clinical and Regulatory Advisory Board
Joanne Curley 54 2021 Independent Director
Mary L. Rotunno 63 2021 Independent Director
Margaret M. FitzPatrick 57 2021 Independent Chair of the Board
Gerard Sanacora - 2015 Member of Clinical & Regulatory Advisory Board
Maurizio Fava - 2015 Member of Clinical & Regulatory Advisory Board
Mark Steven Wallace - 2017 Member of Clinical & Regulatory Advisory Board
Ann Michelle Cunningham 55 2019 Director
Jon S. Saxe 88 2000 Independent Lead Director and Life Science Advisor
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VTGN Comments

Write your thoughts about VistaGen Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Sardar Saleh
Sardar Saleh May 14, 2021 10:49
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to the moon 🌙
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email